ULTRASOUND MEDIATED PERMEABILITY-DRUG DELIVERY

Information

  • Research Project
  • 6498983
  • ApplicationId
    6498983
  • Core Project Number
    R44HL062024
  • Full Project Number
    5R44HL062024-03
  • Serial Number
    62024
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/15/1999 - 26 years ago
  • Project End Date
    1/31/2005 - 20 years ago
  • Program Officer Name
    SKARLATOS, SONIA
  • Budget Start Date
    2/1/2002 - 23 years ago
  • Budget End Date
    1/31/2005 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    3
  • Suffix
  • Award Notice Date
    1/16/2002 - 23 years ago
Organizations

ULTRASOUND MEDIATED PERMEABILITY-DRUG DELIVERY

DESCRIPTION (Verbatim from Applicant's Abstract): The goal of this project is to demonstrate the feasibility of using ultrasound to temporarily make vascular tissue and cell membranes more permeable to deliver drug to vessel walls. EKOS has developed an ultrasound-catheter device for transmural drug delivery that may be useful in the treatment of restenosis following balloon angioplasty. Local ultrasound enhanced drug delivery may increase the usefulness of drugs that are too toxic or expensive to deliver systemically. The results of Phase I demonstrated that ultrasound can make eukaryotic cells permeable for the uptake of exogenous materials. The permeability was correlated with aspects of the acoustic signature radiated by the cavitation field in the cell suspension during exposure. The aims of Phase II are to determine the effect of acoustic parameters on molecular uptake and cell viability in simple cell suspensions and more complex organized tissues and to develop a measure for the cavitation mediated permeability based on acoustic signature analysis. This measure will give a real time feedback predicting the bioeffects for optimizing therapy delivery. PROPOSED COMMERCIAL APPLICATION: The EKOS product will be an ultrasound catheter device that actively delivers drug into the artery wall for the treatment of restenosis.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    331168
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:331168\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    EKOS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    BOTHELL
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98011
  • Organization District
    UNITED STATES